Two small molecule lead compounds as new antifungal agents effective against Candida albicans and Saccharomyces cerevisiae
Novelty in Biomedicine,
Vol. 2 No. 2 (2014),
21 June 2014
,
Page 47-52
https://doi.org/10.22037/nbm.v2i2.5993
Abstract
Background: Antifungal drug resistance and few numbers of available drugs limit therapeutic options against fungal infections. The present study was designed to discover new antifungal drugs.
Materials and Methods: This study was carried out in two separate steps, that is, in silico lead identification and in vitro assaying of antifungal potential. A structural data file of a ternary complex of fusicuccin (legend), C terminus of H+-ATPase and 14-3-3 regulatory protein (1o9F.pdb file) was used as a model. Computational screening of a virtual 3D database of drug-like molecules was performed and selected small molecules, resembling the functional part of the ligand performing ligand docking, were tested using ArgusLab (4.0.1). Two lead compounds, 3-Cyclohexan propionic acid (CXP) and 4-phenyl butyric acid (PBA) were selected according to their ligation scores. Standard Strains of Candida albicans and Saccharomyces cerevisiae were used to measure the antifungal potential of the two identified lead compounds against the fungi using micro-well plate dilution assay.
Results: Ligation scores for CXP and PBA were -9.33744 and -10.7259 kcal/mol, respectively, and MIC and MFC of CXP and PBA against the two yeasts were promising.
Conclusion: The evidence from the present study suggests that CXP and PBA possess potentially antifungals properties.
- Computer aided drug design
- Fungicide
- Fusicoccin
- H -ATPase
How to Cite
References
Gschwend DA, Good AC, Kuntz ID. Molecular docking towards drug discovery. Journal of Molecular Recognition. 1996;9:175-86.
Haustedt L, Mang C, Siems K, Schiewe H. Rational approaches to natural-product-based drug design. Current opinion in drug discovery & development. 2006;9:445.
Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Current Opinion in Chemical Biology. 2002;6:439-46.
Joseph-McCarthy D, Baber J, Feyfant E, Thompson D, Humblet C. Lead optimization via high-throughput molecular docking. Current opinion in drug discovery & development. 2007;10:264.
Sze H, Li X, Palmgren MG. Energization of plant cell membranes by H+-pumping ATPases: regulation and biosynthesis. The Plant Cell Online. 1999;11:677-89.
Perlin DS, SETO‐YOUNG D, Monk BC. The Plasma Membrane H+‐ATPase of Fungi. Annals of the New York Academy of Sciences. 1997;834:609-17.
Svennelid F, Olsson A, Piotrowski M, Rosenquist M, Ottman C, Larsson C, et al. Phosphorylation of Thr-948 at the C terminus of the plasma membrane H+-ATPase creates a binding site for the regulatory 14-3-3 protein. The Plant Cell Online. 1999;11:2379-91.
Yaffe MB. How do 14-3-3 proteins work?–Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS letters. 2002;513:53-7.
Sehnke PC, DeLille JM, Ferl RJ. Consummating Signal Transduction The Role of 14-3-3 Proteins in the Completion of Signal-Induced Transitions in Protein Activity. The Plant Cell Online. 2002;14:S339-S54.
Ballio A, Brufani M, Casinovi C, Cerrini S, Fedeli W, Pellicciari R, et al. The structure of fusicoccin A. Cellular and Molecular Life Sciences. 1968;24:631-5.
Marre E. Fusicoccin: a tool in plant physiology. Annual Review of Plant Physiology. 1979;30:273-88.
Würtele M, Jelich-Ottmann C, Wittinghofer A, Oecking C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. The EMBO journal. 2003;22:987-94.
Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell. 1997;91:961.
Gardino AK, Smerdon SJ, Yaffe MB. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Seminars in cancer biology; 2006: Elsevier. p. 173-82.
Hurd TW, Fan S, Liu C-J, Kweon HK, Hakansson K, Margolis B. Phosphorylation-dependent binding of 14-3-3 to the polarity protein Par3 regulates cell polarity in mammalian epithelia. Current biology. 2003;13:2082-90.
Mishra NN, Prasad T, Sharma N, Payasi A, Prasad R, Gupta DK, et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. Acta microbiologica et immunologica Hungarica. 2007;54:201-35.
Palmgren MG, Harper JF. Pumping with plant P-type ATPases. Journal of Experimental Botany. 1999;50:883.
Serrano R, Kielland-Brandt MC, Fink GR. Yeast plasma membrane ATPase is essential for growth and has homology with (Na+ + K+), K+-and Ca2+-ATPases. 1986.
Pardo JM, Serrano R. Structure of a plasma membrane H+-ATPase gene from the plant Arabidopsis thaliana. Journal of Biological Chemistry. 1989;264:8557-62.
Searls DB. Using bioinformatics in gene and drug discovery. Drug Discovery Today. 2000;5:135-43.
Terstappen GC, Reggiani A. In silico research in drug discovery. Trends in pharmacological sciences. 2001;22:23-6.
Good A. Structure-based virtual screening protocols. Current opinion in drug discovery & development. 2001;4:301.
Walters WP, Murcko MA. Prediction of ‘drug-likeness’. Advanced drug delivery reviews. 2002;54:255-71.
- Abstract Viewed: 605 times
- PDF Downloaded: 332 times